Form 4: ATAI Life Sciences Executive Sahil Kirpekar Sells Shares to Cover Tax Obligations

Sahil Kirpekar, Chief Business Officer of ATAI Life Sciences N.V., sold 48,563 common shares on March 21, 2025, at a price of $1.35 per share to cover tax liabilities arising from the vesting of restricted stock units.

Summary

• On March 21, 2025, Sahil Kirpekar, the Chief Business Officer of ATAI Life Sciences N.V., sold 48,563 common shares.
• The shares were sold at a price of $1.35 per share.
• The sale was executed to satisfy the reporting person's tax liability on the vesting of restricted stock units.
• Following the transaction, Kirpekar directly owns 115,636 common shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The sale of shares to cover tax obligations is a neutral event and doesn't necessarily reflect a positive or negative sentiment towards the company's future prospects.

Industry Context

Executive share sales are a common occurrence in publicly traded companies, often related to compensation and tax obligations. The sale itself doesn't necessarily indicate a negative outlook for the company, but it can be viewed in the context of overall insider sentiment.

Stakeholder Impact

• The sale of shares could have a minor impact on shareholders, potentially causing a slight decrease in share price due to increased selling pressure, although the amount is unlikely to be significant.

Key Dates

Keywords

ATAI Life Sciences, Sahil Kirpekar, Form 4, Share Sale, Executive, Common Shares, Restricted Stock Units, Tax Liability